# Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers

> **NCT04666012** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cellid Co., Ltd.** · enrollment: 150 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** AdCLD-CoV19

## Key facts

- **NCT ID:** NCT04666012
- **Lead sponsor:** Cellid Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-29
- **Primary completion:** 2021-07-09
- **Final completion:** 2023-03-27
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04666012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04666012, "Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04666012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*